Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Open Access
Abstract
Immunotherapy-based combinations, driven by PD-1, PD-L1, and CTLA-4 inhibitors, has altered the treatment landscape for metastatic renal cell carcinoma (RCC). Despite significant improvements in clinical outcomes, many patients do not experience deep or lasting benefits. Recent efforts to determine which patients are most likely to benefit from immunotherapy and immunotherapy-based combinations have shown promise but have not yet affected clinical practice. PD-L1 expression via immunohistochemistry (IHC) has shown promise in a few clinical trials, although variations in the IHC assays as well as the use of different values for positivity presents unique challenges for this potential biomarker. Several other candidate biomarkers were investigated including tumor mutational burden, gene expression signatures, single gene mutations, human endogenous retroviruses, the gastrointestinal microbiome, and peripheral blood laboratory markers. While individually these biomarkers have yet to explain the heterogeneity of treatment response to immunotherapy, using aggregate information from these biomarkers may inform clinically useful predictive biomarkers.Keywords
This publication has 79 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Comprehensive molecular characterization of clear cell renal cell carcinomaNature, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment StrategiesThe Oncologist, 2012
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted TherapyJournal of Clinical Oncology, 2009
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinomaCancer, 2005
- Immunotherapy for advanced renal cell cancer2004
- Initial sequencing and analysis of the human genomeNature, 2001